Editorial
doi: 10.1038/bjc.1997.568.
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
- PMID: 9400932
- PMCID: PMC2228166
- DOI: 10.1038/bjc.1997.568
Item in Clipboard
Editorial
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
Br J Cancer.
1997.
Free PMC article
No abstract available
Comment on
-
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.Br J Cancer. 1997;76(11):1494-9. doi: 10.1038/bjc.1997.584. Br J Cancer. 1997. PMID: 9400948 Free PMC article. Clinical Trial.
-
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.Br J Cancer. 1997;76(11):1500-8. doi: 10.1038/bjc.1997.585. Br J Cancer. 1997. PMID: 9400949 Free PMC article. Clinical Trial.
Similar articles
-
Clinical use of topoisomerase I inhibitors in anticancer treatment.Med Pediatr Oncol. 2000 Oct;35(4):385-402. doi: 10.1002/1096-911x(20001001)35:4<385::aid-mpo1>3.0.co;2-e. Med Pediatr Oncol. 2000. PMID: 11025469 Review.
-
Phase I clinical trial of weekly combined topotecan and irinotecan.Am J Clin Oncol. 2001 Aug;24(4):336-40. doi: 10.1097/00000421-200108000-00003. Am J Clin Oncol. 2001. PMID: 11474256 Clinical Trial.
-
The development of camptothecin analogs in childhood cancers.Oncologist. 2001;6(6):506-16. doi: 10.1634/theoncologist.6-6-506. Oncologist. 2001. PMID: 11743213 Review.
-
Clinical development of topoisomerase-interactive drugs.Adv Pharmacol. 1994;29B:1-31. doi: 10.1016/s1054-3589(08)61129-1. Adv Pharmacol. 1994. PMID: 8996599 Review. No abstract available.
-
Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?Leuk Res. 2003 Jan;27(1):1-3. doi: 10.1016/s0145-2126(02)00219-9. Leuk Res. 2003. PMID: 12479845 No abstract available.
Cited by
-
Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.Int J Mol Sci. 2020 Jul 12;21(14):4919. doi: 10.3390/ijms21144919. Int J Mol Sci. 2020. PMID: 32664667 Free PMC article. Review.
-
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.Br J Cancer. 2003 Aug 18;89(4):617-24. doi: 10.1038/sj.bjc.6601147. Br J Cancer. 2003. PMID: 12915867 Free PMC article. Clinical Trial.
-
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.Br J Cancer. 2003 Mar 24;88(6):808-13. doi: 10.1038/sj.bjc.6600800. Br J Cancer. 2003. PMID: 12644814 Free PMC article. Clinical Trial.
-
Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis.Integr Cancer Ther. 2024 Jan-Dec;23:15347354241242110. doi: 10.1177/15347354241242110. Integr Cancer Ther. 2024. PMID: 38567795 Free PMC article.
-
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.Invest New Drugs. 2003 Aug;21(3):347-52. doi: 10.1023/a:1025476813365. Invest New Drugs. 2003. PMID: 14578683 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
